Evidence map›Paper›PMID 42145073›Full record

ArticleClinical and translational medicine2026

Tumour-derived SAA1 reprogrammes macrophages to promote CXCL1-mediated metastasis in Ovarian Cancer.

Xuan Zhou, Huangyang Meng, Qianjing Chang, Jingjing Ren, Meichen Wen, Lin Zhang, Wenjun Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuan ZhouDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Huangyang MengDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0003-2662-915X
Qianjing ChangDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jingjing RenDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Meichen WenDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Lin ZhangDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0003-3101-8476
Wenjun ChengDepartment of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-5977-6589

Funding

China Postdoctoral Science Foundation 2024M751216General Project of Yili Clinical Medical Research Institute 2022Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project-Key Project ZD202014Jiangsu Provincial Key Medical Discipline Fund ZDXK202210Jiangsu Provincial Maternal and Child Health Research Fund F202131National Natural Science Foundation of China 82373387National Natural Science Foundation of China 82404004Natural Science Fund of Jiangsu Province BE2023776Natural Science Fund of Jiangsu Province BK20210971Natural Science Fund of Jiangsu Province BK20231265
6 · The paper itself

Abstract

Patients with advanced high-grade serous ovarian carcinoma (HGSOC) often experience extremely poor prognoses due to extensive peritoneal metastases, yet the underlying driving mechanisms remain unclear. This study reveals that serum amyloid A1 (SAA1) is markedly upregulated in late-stage HGSOC and is closely associated with poor prognosis and distant metastasis. These findings were validated through both single-cell RNA sequencing and clinical specimen analyses. Surprisingly, SAA1 does not directly promote tumour cell proliferation or migration. Instead, it reshapes the immunosuppressive tumour microenvironment by activating FPR2

Indexed as

Chemokine CXCL1MacrophagesOvarian NeoplasmsSerum Amyloid A ProteinAnimalsCell Line, TumorFemaleHumansMiceNeoplasm MetastasisReceptors, Formyl PeptideReceptors, LipoxinTumor-Associated MacrophagesTumor MicroenvironmentChemokine CXCL1CXCL1 protein, humanFPR2 protein, humanReceptors, Formyl PeptideReceptors, LipoxinSAA1 protein, humanSerum Amyloid A ProteinCXCL1macrophagemetastasisovarian cancerSAA1tumour microenvironment

Identifiers

PMID42145073
PMCPMC13181338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.